CIB walks into today's print having already recovered from the dip that followed the August 3 report, closing at $91.47 Monday — up nearly 3% on the day and 10% higher over the past month — yet still trading well above a consensus that most of the Street hasn't refreshed since spring.
The analyst story is the sharpest tension heading into this release. Goldman Sachs' Tito Labarta upgraded to Buy on July 28 with a $98 target — the only bullish outlier among the major houses — while JPMorgan and UBS sit on Neutral with targets of $70 and $72 respectively, both set in April and May before the stock re-rated through those levels. B of A moved off Underperform in June, lifting its target to $75, also now well below the current price. The consensus mean of $72.34 is nearly 20% beneath where CIB actually trades; that gap reflects targets that haven't caught up rather than a coherent bearish view, but it does mean Goldman is essentially alone in endorsing the stock at current levels. The debate isn't really about the company's fundamentals — it's about whether the re-rating that's already happened is justified or has run ahead of itself.
Positioning offers little alarm on either side. Short interest has fallen sharply — down roughly 47% over the past month to around 456,000 shares — and borrow availability is essentially unlimited, with no meaningful pressure in the lending market. The cost to borrow a trivial 0.31% confirms there is no short-side conviction. Options are modestly more defensive than usual: the put/call ratio at 0.53 runs about one standard deviation above its 20-day average of 0.45, a mild elevation rather than a signal of genuine fear. The ORTEX short score of 26.8 has drifted gently lower over the past week, reinforcing the picture of a market leaning cautiously bullish rather than bracing for a fall.
The prior August 3 print produced a modest one-day loss of about 2.7%, with the stock giving back roughly 1% over the following five days — a muted reaction for a stock that had moved this far this fast. Valuation has re-rated meaningfully: price-to-book now at 1.86x is up about 6% over the past month, while the P/E of 8.75x has compressed slightly on the week. Today's result is less a test of whether Bancolombia's underlying business is healthy and more a test of whether Goldman's lone Buy conviction — and the $98 implied by its target — can survive contact with whatever margin and loan-growth data the company actually delivers.
See the live data behind this article on ORTEX.
Open CIB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
